Which enzyme is primarily associated with the reduction of NADP+ to NADPH in the pentose phosphate pathway?
Which one of the following statements concerning gluconeogenesis is correct?
Which of the following is an amino sugar formed from fructose-6-phosphate?
Which of the following statements BEST describes the net ATP production in glycolysis?
Which glycogen storage disease also presents as a lysosomal storage disease?
Glucose is converted to glucuronate by which process?
Which of the following substances does not inhibit glycolysis?
What cofactor is required for the proper functioning of glucose-6-phosphate dehydrogenase?
Increased uric acid levels are seen in which glycogen storage disease ?
GLUT2 plays a functionally important role mainly in?
Explanation: ***G6PD*** - **Glucose-6-phosphate dehydrogenase (G6PD)** catalyzes the first committed step in the pentose phosphate pathway, converting **glucose-6-phosphate** to **6-phosphogluconolactone**. - This reaction involves the reduction of **NADP+ to NADPH**, making G6PD the primary enzyme for NADPH production in this pathway. *APDH* - **APDH (adenosine phosphosulfate reductase)** is involved in sulfur metabolism and has no direct role in the pentose phosphate pathway or NADPH production. - This enzyme primarily functions in prokaryotes for the **reduction of APS (adenosine 5'-phosphosulfate)**. *α-keto glutarate dehydrogenases* - **Alpha-ketoglutarate dehydrogenase** is a mitochondrial enzyme part of the **Krebs cycle**, converting **alpha-ketoglutarate to succinyl-CoA**. - This enzyme is crucial for ATP production and generates **NADH**, not NADPH, in its reaction. *None of the options* - This option is incorrect because **G6PD** is indeed the primary enzyme responsible for NADPH generation in the pentose phosphate pathway.
Explanation: ***It is important in maintaining blood glucose during the normal overnight fast.*** - **This is the BEST answer** as it emphasizes the **primary physiological role** of gluconeogenesis in human metabolism. - During the **overnight fast** (8-12 hours), hepatic glycogen stores become depleted, making gluconeogenesis the **critical mechanism** to maintain blood glucose for glucose-dependent tissues like the **brain** (requires ~120g glucose/day) and **red blood cells**. - Without gluconeogenesis, blood glucose would drop dangerously during fasting, leading to hypoglycemia and neurological dysfunction. *It occurs primarily in the liver.* - This statement is **technically correct** - the liver accounts for approximately **90%** of total gluconeogenesis under normal conditions. - However, the **kidney cortex** also contributes significantly (10% normally, up to 40% during prolonged fasting), and the **intestine** plays a minor role. - While true, this is more of a **anatomical fact** rather than highlighting the critical physiological importance of the pathway, making it a less comprehensive answer than Option 1. *It is stimulated by elevated levels of acetyl CoA.* - This statement is **biochemically correct** - **Acetyl-CoA** is an important **allosteric activator** of **pyruvate carboxylase**, the first committed enzyme of gluconeogenesis. - However, this represents just **one regulatory mechanism** at the enzymatic level, not the overall physiological significance. - Primary regulation occurs through **hormones** (glucagon, cortisol, epinephrine) that coordinate the entire pathway, making this a narrower answer than Option 1. *It is primarily inhibited by insulin.* - This statement is also **correct** - **Insulin** is the primary hormonal **inhibitor** of gluconeogenesis. - Insulin suppresses gluconeogenesis by inhibiting key enzymes (PEPCK, glucose-6-phosphatase) and decreasing transcription of gluconeogenic genes. - However, this describes **inhibition** rather than the positive physiological role, making it less representative of gluconeogenesis's essential function than Option 1. **Note:** All four statements are technically correct, but Option 1 best captures the **essential physiological importance** of gluconeogenesis in human metabolism, which is why it is the preferred answer for this question.
Explanation: ***Glucosamine-6-phosphate*** - This amino sugar is directly synthesized from **fructose-6-phosphate** via a transamidation reaction, where an amino group replaces a hydroxyl group. - It is a key intermediate in the biosynthesis of other **amino sugars** and **glycosaminoglycans**. *N-acetylglucosamine-6-phosphate* - This is formed from **glucosamine-6-phosphate** by the addition of an **acetyl group**, making it a subsequent product, not the initial amino sugar from fructose-6-phosphate. - The N-acetylation step is crucial for its role in cellular signaling and structural components. *Galactosamine-6-phosphate* - While an amino sugar, **galactosamine-6-phosphate** is derived from UDP-N-acetylglucosamine, not directly from fructose-6-phosphate. - Its formation involves an **epimerization** step of an existing N-acetylglucosamine structure. *UDP-N-acetylglucosamine* - This is an **activated form** of N-acetylglucosamine, formed by the addition of UTP to N-acetylglucosamine-1-phosphate. - It serves as a precursor for the synthesis of complex **carbohydrates** and glycoproteins, far downstream from fructose-6-phosphate.
Explanation: ***Glycolysis produces a net gain of 2 ATP per glucose molecule*** - In the initial "investment" phase of glycolysis, **2 ATP molecules are consumed** to phosphorylate glucose. - In the subsequent "payoff" phase, **4 ATP molecules are produced** through substrate-level phosphorylation, resulting in a net gain of 2 ATP. *Glycolysis produces 2 molecules of pyruvate* - While glycolysis does produce **2 molecules of pyruvate** from one glucose molecule, this statement describes the end product of the pathway, not the net ATP production. - Pyruvate is a crucial product that can be further metabolized in aerobic or anaerobic conditions, but it does not directly represent the energy yield in terms of ATP. *Hexokinase consumes ATP during glycolysis* - **Hexokinase** is indeed the enzyme that catalyzes the first ATP-consuming step in glycolysis, phosphorylating glucose to glucose-6-phosphate. - However, this statement describes only one aspect of ATP utilization within the pathway and does not account for the total ATP produced or the overall net gain. *Aldolase catalyzes the conversion of fructose-1,6-bisphosphate into two three-carbon molecules* - **Aldolase** is a key enzyme in glycolysis responsible for cleaving **fructose-1,6-bisphosphate** into dihydroxyacetone phosphate and glyceraldehyde-3-phosphate. - This step is part of the preparatory phase of glycolysis but does not directly describe the net ATP production.
Explanation: ***Pompe's disease*** - Also known as **glycogen storage disease type II**, it is caused by a deficiency of **acid alpha-glucosidase (GAA)**, a *lysosomal enzyme*. - This deficiency leads to the accumulation of **glycogen in lysosomes**, particularly affecting muscle tissue, thereby earning its classification as both a glycogen storage disease and a lysosomal storage disease. *Von Gierke's disease* - This is **glycogen storage disease type I** and is due to a deficiency in **glucose-6-phosphatase**. - It primarily affects the **liver and kidneys**, causing severe **hypoglycemia** and **lactic acidosis**, but it is not classified as a lysosomal storage disease. *McArdle's disease* - This is **glycogen storage disease type V**, caused by a deficiency in **muscle glycogen phosphorylase (myophosphorylase)**. - It manifests as **exercise intolerance** and muscle pain, but it does not involve lysosomal enzyme defects or glycogen accumulation in lysosomes. *Andersen's disease* - This is **glycogen storage disease type IV**, caused by a deficiency in the **glycogen branching enzyme**. - It leads to the formation of **abnormal glycogen structures**, primarily affecting the liver and causing early liver failure, but it is not a lysosomal storage disorder.
Explanation: ***Oxidation of the terminal alcohol group*** - **Glucuronate** is formed by the **oxidation of the C-6 carbon** (the terminal primary alcohol group) of glucose. - This process is crucial for the detoxification of various substances in the body, as glucuronate is a key component in **glucuronidation reactions**. *Oxidation of aldehyde group* - Oxidation of the **aldehyde group (C-1)** of glucose typically forms **gluconic acid**, not glucuronate. - Gluconate is derived from the oxidation of the first carbon, while glucuronate is derived from the oxidation of the last carbon. *Oxidation of both* - If both the aldehyde group (C-1) and the terminal alcohol group (C-6) of glucose were oxidized, it would result in the formation of **glucaric acid** (saccharic acid), not glucuronate. - Glucaric acid has two carboxyl groups, one at each end of the molecule. *None of the options* - This option is incorrect because the specific biochemical pathway for glucuronate formation involves the oxidation of the terminal alcohol group. - The conversion of glucose to glucuronate is a well-established metabolic process.
Explanation: ***Fluoroacetate*** - **Fluoroacetate** is not a direct inhibitor of glycolysis. Instead, it is metabolized to **fluorocitrate**, which then acts as an inhibitor of **aconitase** in the **Krebs cycle (TCA cycle)**, thereby affecting cellular respiration at a later stage. - Its primary role in metabolic inhibition is within the **mitochondria**, impacting energy production via the TCA cycle rather than the glycolytic pathway. *Fluoride* - **Fluoride** is a known inhibitor of **enolase**, an enzyme in the penultimate step of glycolysis. - It forms a complex with **magnesium** and **phosphate** to block the active site of enolase, preventing the conversion of 2-phosphoglycerate to phosphoenolpyruvate. *Arsenite* - **Arsenite** inhibits glycolysis by targeting enzymes containing **sulfhydryl (–SH) groups**, particularly **glyceraldehyde-3-phosphate dehydrogenase (GAPDH)**, a critical enzyme in the glycolytic pathway. - It also inhibits the **pyruvate dehydrogenase complex** (linking glycolysis to the TCA cycle) and TCA cycle enzymes like **α-ketoglutarate dehydrogenase**, thereby affecting multiple stages of cellular respiration. *Iodoacetate* - **Iodoacetate** is a potent inhibitor of the enzyme **glyceraldehyde-3-phosphate dehydrogenase (GAPDH)**. - It specifically alkylates the **cysteine residue** at the active site of GAPDH, preventing the conversion of glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate, thereby blocking glycolysis.
Explanation: ***NADP*** - **NADP+** (nicotinamide adenine dinucleotide phosphate) acts as the **electron acceptor** in the **glucose-6-phosphate dehydrogenase (G6PD)** reaction, becoming **NADPH**. - **NADPH** is crucial for maintaining the **redox balance** in cells, particularly in red blood cells, by reducing **oxidative stress**. *NAD* - **NAD+** (nicotinamide adenine dinucleotide) is a primary cofactor for many **dehydrogenase reactions** in catabolic pathways like **glycolysis** and the **Krebs cycle**. - It primarily functions as an electron acceptor in pathways that generate **ATP**, distinct from the role of **NADPH** in reductive biosynthesis and antioxidant defense. *FAD* - **FAD** (flavin adenine dinucleotide) is a coenzyme derived from **riboflavin (vitamin B2)** that is involved in various redox reactions, often in the form of **flavoproteins**. - Enzymes like **succinate dehydrogenase** in the electron transport chain utilize **FAD** as an electron acceptor, which is not the case for G6PD. *FMN* - **FMN** (flavin mononucleotide) is another coenzyme derived from **riboflavin**, structurally similar to FAD but lacking the additional adenosine monophosphate. - It participates in electron transfer reactions, particularly within **complex I** of the **electron transport chain**, but is not a cofactor for G6PD.
Explanation: ***Type I (Von Gierke's disease)*** - In **Von Gierke's disease**, the deficiency of **glucose-6-phosphatase** leads to accumulation of glucose-6-phosphate in hepatocytes. - **Hyperuricemia** occurs due to: 1. **Increased purine degradation** - Metabolic stress leads to accelerated ATP breakdown and increased uric acid production 2. **Decreased renal excretion** - Lactic acidosis (from G6P → pyruvate → lactate) competitively inhibits uric acid secretion in renal tubules 3. **Enhanced purine synthesis** - Increased availability of ribose-5-phosphate from pentose phosphate pathway - Classic triad: **Hepatomegaly, hypoglycemia, and lactic acidosis with hyperuricemia** *Type II (Pompe disease)* - Caused by a deficiency of **acid alpha-glucosidase** (acid maltase), leading to glycogen accumulation in **lysosomes**. - Primarily affects the **heart**, **muscles**, and **liver**, but does not cause hyperuricemia. *Type IV (Andersen disease)* - Results from a deficiency of **glycogen branching enzyme**, leading to the formation of abnormal glycogen with long, unbranched chains. - Primarily affects the **liver** and **spleen**, causing cirrhosis and hepatic failure, but not hyperuricemia. *Type III (Cori disease)* - Caused by a deficiency of **glycogen debranching enzyme** (amylo-1,6-glucosidase), leading to abnormal accumulation of glycogen with short outer branches. - Presents with hepatomegaly, hypoglycemia, and muscle weakness, but **hyperuricemia is not a characteristic feature**.
Explanation: ***Pancreatic beta cells*** - **GLUT2** acts as a **glucose sensor** in pancreatic beta cells, which is its **most functionally critical role** in the body. - Its high Km (~15-20 mM, low affinity) ensures that glucose uptake is **proportional to blood glucose concentration**, enabling the beta cells to accurately sense glucose levels and secrete insulin accordingly. - This glucose-sensing mechanism is **essential for maintaining glycemic homeostasis** and makes GLUT2's role in beta cells uniquely important compared to its presence in other tissues. - Without functional GLUT2 in beta cells, the body cannot properly regulate insulin secretion in response to changing glucose levels. *Liver* - While **GLUT2** is abundantly expressed in hepatocytes and allows for bidirectional glucose transport (both uptake and release), its role here is **facilitative rather than regulatory**. - The liver has multiple other glucose-regulating mechanisms (glucokinase, glucose-6-phosphatase, glycogen metabolism). - GLUT2's function in the liver is important but not as uniquely critical as its glucose-sensing role in beta cells. *Skeletal muscle tissue* - **Skeletal muscle** primarily utilizes **GLUT4** (not GLUT2) for insulin-dependent glucose uptake. - **GLUT2** is not significantly expressed in skeletal muscle tissue. - This makes GLUT2 functionally unimportant in skeletal muscle. *Kidney* - The **kidney** expresses **GLUT2** in proximal tubule cells where it participates in glucose reabsorption from the glomerular filtrate. - However, this role is **secondary to SGLT2** (sodium-glucose cotransporter 2), which performs the primary active reabsorption. - GLUT2's function here is important but not the **"mainly"** critical role compared to its glucose-sensing function in beta cells.
Carbohydrate Chemistry and Classification
Practice Questions
Glycolysis: Reactions and Regulation
Practice Questions
Gluconeogenesis: Reactions and Regulation
Practice Questions
Glycogen Metabolism: Synthesis and Breakdown
Practice Questions
Glycogen Storage Diseases
Practice Questions
Pentose Phosphate Pathway
Practice Questions
Metabolism of Fructose and Galactose
Practice Questions
Disorders of Fructose and Galactose Metabolism
Practice Questions
Blood Glucose Regulation
Practice Questions
Diabetes Mellitus: Biochemical Aspects
Practice Questions
Glycosylation and Glycoproteins
Practice Questions
Lactose Intolerance and Galactosemia
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free